Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Xi Website

Liqiang Xi, M.D.

Portait Photo of Liqiang Xi
Laboratory of Pathology
Molecular Diagnostics and Immunohistochemistry
Staff Scientist
Center for Cancer Research
National Cancer Institute
Building 10, Room 2N110
Bethesda, MD 20892


Dr. Xi completed his medical education in China. He obtained his M.S. in toxicology and occupational health from the Chinese Center for Disease Control and Prevention. He pursued postdoctoral training at the UC Berkeley School of Public Health and the University of Pittsburgh Graduate School of Public Health, where he studied biomarkers of environmental carcinogenesis. While in Pittsburgh he also studied and obtained his M.S. in information science with a focus in bioinformatics. Prior to joining the NCI Laboratory of Pathology, Dr. Xi was a research assistant professor at the Department of Pathology, Mount Sinai School of Medicine, New York. He has co-authored 2 patents and over 60 scientific publications.


Dr. Xi worked with a translational clinical research team for 8 years at the University of Pittsburgh School of Medicine and later at the Mount Sinai School of Medicine, New York. This research was focused on identification of molecular markers to reliably detect cancer metastasis to lymph nodes or blood, and on molecular signatures of cancer by employing the cutting-edge technologies at the time, such as TaqMan real-time quantitative RT-PCR, gene expression microarrays, microRNA expression profiling, and genome wide whole exon microarrays.

At the NCI, Dr. Xi serves as the technical director for the Molecular Diagnostics Laboratory, Laboratory of Pathology, supervising a broad array of CLIA-certified molecular diagnostics activities from traditional fragment analysis for detection of B cell and T cell clonality in lymphoma and RT-PCR assays for fusion gene detection in sarcoma, to cancer gene mutation testing using the most cutting-edge technology, next generation sequencing. In addition to research and development of new molecular tests that support molecular diagnostics and personalized cancer therapies, Dr. Xi's research interests currently focus on analysis of circulating tumor DNA in melanoma to measure the immunotherapy response, and targeted mutational analysis of uncommon types of lymphoma.

This page was last updated on 5/27/2014.